NEW YORK (GenomeWeb) – Genalice and Knome said today that the Swiss Foundation for People with Rare Diseases has selected both companies' solutions to process and analyze their next-generation sequencing data.
The combined platform will include Genalice Map, Genalice's NGS data preprocessing solution, connected to KnoSys, Knome's informatics and genomics interpretation system. The combined technologies will enable "unprecedented control over our data from end-to-end" and will enable "our work to advance considerably," Gabor Matyas, one of the members of the foundation, said in a statement.
"With Genalice Map, we significantly reduce the NGS data bottlenecks for align[ment] and call[ing] with regard to speed, quality, and cost," he said. "The connection to the KnoSys then takes our analysis to the next step by enabling the annotation and interpretation of our human NGS data."
"The Swiss Foundation for People with Rare Diseases represents an incredible opportunity for Genalice and Knome to work together on creating a system unlike any other," Knome President and CEO Wolfgang Daum said in a statement. "We are eagerly awaiting the results they are able to achieve using the combined strengths of both platforms."